PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

PARP inhibitors have emerged as a promising class of anticancer agents approved for the treatment of ovarian, breast, prostate, and pancreatic cancer. These inhibitors target PARP enzymes involved in DNA repair pathways and exhibit remarkable efficacy in cancers with genetic deficiencies in the homo...

Ausführliche Beschreibung